EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT

GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.  

HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETING

As described in the proxy materials, stockholders of record as of the record date of March 25, 2021 are eligible to participate in and ask questions during the Virtual Annual Meeting by visiting and entering their 16-digit Control Number provided on the proxy card, voting instruction form or notice received from the Company to log into this website. Only one stockholder per 16-digit Control Number can access the Virtual Annual Meeting.

Beneficial owners of shares held in street name will need to follow the instructions provided by the broker, bank or other nominee that holds their shares.  

Those without a Control Number may attend as guests in listen-only mode and will not have the option to vote their shares or ask questions during the Virtual Annual Meeting.

ALL PARTICIPANTS ARE ENCOURAGED TO LOG IN AND ACCESS THE WEBCAST 15 MINUTES BEFORE THE VIRTUAL ANNUAL MEETING BEGINS.

Further instructions on how to attend, participate in and vote at the Virtual Annual Meeting, including how to demonstrate your ownership of the Company’s common stock as of the record date, are available at .

A replay of the audio webcast will be made available on the .

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information, visit our and follow us on , , and .

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

   

Media Contact:

Matt Hartwig

Director, Media Relations

 



EN
06/05/2021

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Release First Quarter 2024 Financial Results ...

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via . To participate via telephone, please register in advanc...

April 22, 2024 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Continues to Broaden Access, Awareness and Avail...

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding efforts with public interest entities across the country Hundreds of thousands of NARCAN® Nasal Spray cartons are available in over 32,000 retail locations in the U.S., and Emergent is working to increase reach into workplaces, businesses and oth...

March 28, 2024 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufa...

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP). “Quality and compliance excellence remains a top priority for ...

March 25, 2024 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidanceFull Year 2023 Total Revenues of $1.05 billion, which was the mid-point of guidanceFourth Quarter 2023 Net Loss of $50 million and Adjusted EBITDA of $3 millionIssues Q1 2024 and FY 2024 guidance GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023. "Emergent has a long history of helping p...

March 6, 2024 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Finan...

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024 GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks. Conference Call InformationParticipants can access the conference call live via webcast from the page of Emergent’s website. To par...

February 29, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch